| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01514019 | Healthy | Drug: Acebutolol|Drug: Placebo | In-Jin Jang, MD, PhD|Oita University|Seoul National University Hospital|Kyushu University | Phase 4 | 2012-01-01 | 2012-06-19 |
| NCT01743885 | Hemangioma | Drug: Acebutolol|Drug: Propanolol | University Hospital, Montpellier | Phase 3 | 2012-11-01 | 2016-05-31 |
| NCT02439086 | Rectal Neoplasms | Device: PET-CT Scan | Colchester General Hospital|Anglia Ruskin University | 2015-09-01 | 2015-05-08 |
| NCT02189759 | Hypothermia|Newborn | Other: Continuous Kangaroo Mother Care to one hour after birth|Other: Standard Kangaroo Mother Care to one hour after birth|Other: Continuous Kangaroo Mother Care to discharge|Other: Standard Kangaroo Mother Care to discharge | University of Alabama at Birmingham | 2014-06-01 | 2016-01-29 |
| NCT00340470 | Behavioral Intervention | Behavioral: Driver Education | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC) | Phase 3 | 2003-07-24 | 2017-01-24 |
| NCT00684489 | Hypertension | Drug: clinical hypertension specialist-no specific med. Any anti-hypertension meds.|Drug: renin guided therapeutics-no specific med. Any anti-hypertensive med. | Medical University of South Carolina|New York Presbyterian Hospital | 2003-09-01 | 2008-05-22 |
| NCT00911508 | Atrial Fibrillation|Arrhythmia | Device: Left atrial ablation|Drug: Rate or Rhythm Control Therapy | Mayo Clinic|National Heart, Lung, and Blood Institute (NHLBI)|St. Jude Medical|Biosense Webster, Inc. | 2009-08-01 | 2016-04-25 |
| NCT00000522 | Cardiovascular Diseases|Heart Diseases|Hypertension|Vascular Diseases | Behavioral: diet, sodium-restricted|Behavioral: diet, reducing|Behavioral: exercise|Behavioral: alcohol restriction|Drug: chlorthalidone|Drug: acebutolol|Drug: doxazosin|Drug: amlodipine|Drug: enalapril | University of Minnesota - Clinical and Translational Science Institute|National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 | 1985-08-01 | 2016-02-24 |
| NCT00578617 | Atrial Fibrillation|Arrhythmia | Drug: Rate Control|Device: Ablation Therapy|Drug: Rate Control|Drug: Rate control|Drug: Rate control|Drug: Rate control|Drug: Rate Control|Drug: Rate Control|Drug: Rate Control|Drug: Rhythm Control|Drug: Rhythm control|Drug: Rhythm control|Drug: Rhythm control|Drug: Rhythm control|Drug: Rhythm control | Mayo Clinic|Duke Clinical Research Institute|St. Jude Medical | 2006-09-01 | 2012-12-03 |
| NCT01316952 | Hypersensitivity | Drug: Carvedilol immediate release only|Drug: Carvedilol extended release only|Drug: Long acting-blockers|Drug: Other 1-adrenergic antagonists|Drug: Short acting Non-selective-blockers and short acting 1-Selective agents|Other: No-blocker | GlaxoSmithKline | | 2010-06-01 | 2015-04-14 |
